The Society for Immunotherapy of Cancer (SITC) was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of immunotherapy for patients with cancer. Society members include more than 600 influential leaders and scientists engaged in cancer immunology and immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC’s members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer. SITC is a 501(c)(3) nonprofit group.
It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field.
Interaction/Integration: Facilitate the exchange of information and education among basic and translational researchers, clinicians, young investigators, societies and groupssharing the mission of SITC
Innovation: Challenge the thinking and seek the best research in the development of cancer immunotherapy
Translation: Facilitate the transfer of cancer immunology and immunotherapy research from the bench to the clinic and back
Leadership: Define what is new and important and effectively communicate it to all relevant stakeholders
Engage: Strengthen the Society and create a more robust membership base by both attracting new members and retaining the active members through improvement of member benefits and cultivation of key constituency groups
Collaborate: Expand the Society’s impact and influence by establishing relationships with key strategic partners
Learn: Provide education and training about the principles and practice of cancer immunotherapy to be widely recognized as the leading scientific voice in the field